A&A Research Consultants LLC — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$30,257	3
2023	Research	$96,397	19

Breakdown

Who paid Research payments · program years 2023–2025

United Therapeutics Corporation $96,397 19 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $20,000 2 payments
AstraZeneca Pharmaceuticals LP $10,257 1 payment

Studies the money was for Research payments · program years 2023–2025

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $96,397 19 payments
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough $20,000 2 payments
aumlticentre,randomised,open label,parallel group,phase IIIb study to assess the potential for tezepelumab treatedtie pants with severe asthma to reduce background therapy while sustaining asthma control and clinical remission $10,257 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.